透析前慢性肾脏病患者血清铁标志物、补铁与心血管疾病发病率的关联
基于日本慢性肾脏病队列1416例20-75岁透析前CKD患者,中位随访4.12年,发现转铁蛋白饱和度<20%者心血管疾病风险升高(亚分布HR 2.13)、充血性心力衰竭风险升高(亚分布HR 2.42);转铁蛋白饱和度较低者补铁对心血管疾病风险的降低幅度更大(P=0.042)。
要点
- 透析前CKD患者转铁蛋白饱和度<20%与心血管疾病风险升高相关(亚分布HR 2.13)。
- 转铁蛋白饱和度<20%与充血性心力衰竭风险升高相关(亚分布HR 2.42)。
- 转铁蛋白饱和度较低者补铁对心血管疾病风险的降低幅度更大(P=0.042)。
核心结论
- 维持转铁蛋白饱和度>20%并充分补铁可能有效降低透析前CKD患者的心血管疾病事件风险。
研究设计与样本
- 研究纳入1416例20-75岁透析前慢性肾脏病患者,使用日本慢性肾脏病队列数据。
- 暴露指标为血清转铁蛋白饱和度和血清铁蛋白水平,结局指标为任何心血管事件。
- 采用Fine-Gray亚分布风险模型分析血清铁指标与事件时间的关联,采用多变量分数多项式交互方法评估血清铁指标是否修饰补铁与心血管事件的关联。
主要发现
- 中位随访4.12年期间,心血管疾病事件的总体发病率为26.7例/1000人年。
- 血清转铁蛋白饱和度<20%的患者心血管疾病风险升高(亚分布HR 2.13),充血性心力衰竭风险升高(亚分布HR 2.42)。
- 转铁蛋白饱和度较低的患者补铁后心血管疾病风险的降低幅度更大(P=0.042)。
关键数值与推荐
- 血清转铁蛋白饱和度<20%对应的亚分布HR为2.13(心血管疾病)和2.42(充血性心力衰竭)。
- 补铁与转铁蛋白饱和度交互作用的P=0.042。
- 中位随访4.12年,心血管疾病事件总体发病率为26.7例/1000人年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal range of serum iron markers and usefulness of iron supplementation are uncertain in patients with pre-dialysis chronic kidney disease (CKD). We investigated the association between serum iron indices and risk of cardiovascular disease (CVD) events and the effectiveness of iron supplementation using Chronic Kidney Disease Japan Cohort data. METHODS: We included 1416 patients ages 20-75 years with pre-dialysis CKD. The tested exposures were serum transferrin saturation and serum ferritin levels and the outcome measures were any cardiovascular event. Fine-Gray subdistribution hazard models were used to examine the association between serum iron indices and time to events. The multivariable fractional polynomial interaction approach was used to evaluate whether serum iron indices were effect modifiers of the association between iron supplementation and cardiovascular events. RESULTS: The overall incidence rate of CVD events for a median of 4.12 years was 26.7 events/1000 person-years. Patients with serum transferrin saturation <20% demonstrated an increased risk of CVD [subdistribution hazard ratio (HR) 2.13] and congestive heart failure (subdistribution HR 2.42). The magnitude of reduction in CVD risk with iron supplementation was greater in patients with lower transferrin saturations (P = .042). CONCLUSIONS: Maintaining transferrin saturation >20% and adequate iron supplementation may effectively reduce the risk of CVD events in patients with pre-dialysis CKD.
引用
- Hasegawa T, Imaizumi T, Hamano T, et al. Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease. Nephrol Dial Transplant. 2023. PMID: 37202214. doi:10.1093/ndt/gfad096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。